medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2019, Number 2

Next >>

Rev Latin Infect Pediatr 2019; 32 (2)

The enigma of Kawasaki disease

Yamazaki-Nakashimada MA

Language: Spanish
References: 16
Page: 45-47
PDF size: 90.59 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Gámez-González L, Yamazaki-Nakashimada M. Enfermedad de Kawasaki; un vistazo al cincuenteno. Med Sur. 2015; 22: 169-181.

  2. González-Mata A, Ulloa-Gutiérrez R, Brea J, Soza G, Tremoulet AH. Origin and importance of the Latin American Kawasaki Disease Network (REKAMLATINA). Rev Chilena Infectol. 2014; 31: 330-332.

  3. Skochko SM, Jain S, Sun X, Sivilay N, Kanegaye JT, Pancheri J et al. Kawasaki disease outcomes and response to therapy in a multiethnic community: a 10-year experience. J Pediatr. 2018; 203: 408-415.

  4. Marrani E, Burns JC, Cimaz R. How should we classify Kawasaki disease? Front Immunol. 2018; 9: 2974.

  5. Rowley AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis. 2018; 21: 20-25.

  6. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135: e927-e999.

  7. Kim JH, Kang HR, Kim SY, Ban JE. Discrimination of Kawasaki disease with concomitant adenoviral detection differentiating from isolated adenoviral infection. Korean J Pediatr. 2018; 61: 43-48.

  8. Choi JE, Kang HW, Hong YM, Sohn S. C-reactive protein and N-terminal pro-brain natriuretic peptide discrepancy: a differentiation of adenoviral pharyngoconjunctival fever from Kawasaki disease. Korean J Pediatr. 2018; 61: 12-16.

  9. Song E, Kajon AE, Wang H, Salamon D, Texter K, Ramilo O et al. Clinical and virologic characteristics may aid distinction of acute adenovirus disease from Kawasaki disease with incidental adenovirus detection. J Pediatr. 2016; 170: 325-330.

  10. Pal P, Giri PP. Orange-brown chromonychia, a novel finding in Kawasaki disease. Rheumatol Int. 2013; 33: 1207-1209.

  11. Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M et al. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Lancet Child Adolesc Health. 2018; 2: 855-862.

  12. Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019; 393 (10176): 1128-1137.

  13. Tremoulet AH. Adjunctive therapies in Kawasaki disease. Int J Rheum Dis. 2018; 21: 76-79.

  14. Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, Varela-Ortiz J, Muñoz-Ramírez M, Garrido-García M et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease. Pediatr Int. 2018; 60: 781-790.

  15. García-Pavón S, Yamazaki-Nakashimada MA, Báez M, Borjas-Aguilar KL, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol. 2017; 39: 445-451.

  16. Martínez-Pérez M, Gámez-González LB, Moribe-Quintero I, Yamazaki-Nakashimada M. La enfermedad de Kawasaki y el síndrome de choque tóxico. Alerg Asm Inmunol Pediatr. 2018; 27: 18-24.




2020     |     www.medigraphic.com